GynecologyGynecology2079-56962079-5831Consilium Medicum3013610.26442/20795696.2019.1.190285Review ArticleHormonal contraception in women of reproductive age: endocrinological aspectsOvsyannikovaTamara VPhD, Professor of the Department of Obstetrics, Gynecology and Reproductive Medicinedr.otoma@yandex.ruKulikovIlya APhD, Assistant Professor of the Department of Obstetrics, Gynecology and Reproductive Medicine-People’s Friendship University of RussiaI.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation15022019211656809042020Copyright © 2019, Consilium Medicum2019Relevance. Woman’s late reproductive age is a period of complex hormonal adjustment, a preparation for menopause onset. Despite a decline in a reproductive potential and accumulation of gynecological and extragenital diseases in this population a gynecologist has to deal with their contraception as well as a treatment of menstrual disorders and a prevention of hyperplastic processes in the genitals. A search for safe and reliable drugs to solve these problems is extremely important in women of late reproductive period. Aim. Based on date of modern clinical and scientific research a relevance of combined oral contraceptives (COCs) for a safe and reliable contraception as well as for some gynecological diseases treatment and female genital organs hyperplastic and neoplastic diseases prevention was determined. Materials and methods. To write this review a search for domestic and foreign publications in Russian and international search systems (PubMed, eLibrary, etc.) for the last 10 years was conducted. The review includes articles from peer-reviewed literature, data of domestic and foreign clinical guidelines on contraceptive issues and Cochrane Library reviews. Results. Use administration of microdose COCs in the late reproductive period, when taking into account criteria for their acceptability, provides reliable contraception. Based on Cochrane database systematic reviews (2011-2018) reliable data on COCs non-contraceptive therapeutic and prophylactic properties at menstrual cycle disorders, endometriosis, hyperandrogenemia, premenstrual syndrome and polycystic ovary syndrome are presented. Conclusion. A choice of COC containing ethinyl estradiol 20 µg and gestodene (progestogen III generation) 75 µg, given contraindications and current observation, is a rational, effective and safe. This provides effective family planning and maintenance of reproductive health of women of late and perimenopausal age due to its wide therapeutic and prophylactic properties given woman's body features.late reproductive periodcombined oral contraceptivesmenstrual disorderspolycystic ovary syndromeendometriosiscontraceptionethinyl estradiolgestodeneпоздний репродуктивный периодкомбинированные оральные контрацептивынарушения менструального цикласиндром поликистозных яичниковэндометриозконтрацепцияэтинилэстрадиолгестоден[Национальное руководство. Гинекология. Под ред. Г.М.Савельевой, Г.Т.Сухих, В.Н.Серова и др. М.: ГЭОТАР-Медиа, 2017; с. 802-10. [Natsional'noe rukovodstvo. Ginekologiia. Pod red. G.M.Savel'evoi, G.T.Sukhikh, V.N.Serova et al. Moscow: GEOTAR-Media, 2017; p. 802-10 ]][Руководство по контрацепции. Под ред. В.Н.Прилепской. М.: МЕДпресс-информ, 2011; с. 260-95. [Rukovodstvo po kontratseptsii. Pod red. V.N.Prilepskoi. Moscow: MEDpress-inform, 2011; p. 260-95 ]][Прилепская В.Н. Гормональная контрацепция. М.: ГЭОТАР-Медиа, 2014; с. 7-121. [Prilepskaia V.N. Gormonal'naia kontratseptsiia. Moscow: GEOTAR-Media, 2014; p. 7-121 ]][Менопаузальная гормонотерапия и сохранение здоровья женщин зрелого возраста (клинические рекомендации). М., 2014; с. 9-15; 33-40. [Menopauzal'naia gormonoterapiia i sokhranenie zdorov'ia zhenshchin zrelogo vozrasta (klinicheskie rekomendatsii). Moscow, 2014; p. 9-15; 33-40 .]][Medical eligibility criteria for contraceptive use. WHO family planning cornerstone. WHO, 2015.][Национальные медицинские критерии приемлемости методов контрацепции. М., 2012; с. 20-2; 167-9. [Natsional'nye meditsinskie kriterii priemlemosti metodov kontratseptsii. Moscow, 2012; p. 20-2; 167-9 ]][Чижова М.А. Беременность, роды и перинатальные исходы у женщин позднего репродуктивного возраста. Автореф. дис. … канд. мед. наук. М., 2012. [Chizhova M.A. Beremennost', rody i perinatal'nye iskhody u zhenshchin pozdnego reproduktivnogo vozrasta. Avtoref. dis. … kand. med. nauk. Moscow, 2012 ]][Hardman S.M, Gebbie A.E. The contraception needs of the perimenopausal woman. Best Pract Res. Clin Obstet Gynaecol 2014; 28 (6): 903-15.][Kwan I, Onwude J.L. Premenstrual syndrome. BMJ Clin Evid 2015; pii: 0806.][Carmina E, Dewailly D, Escobar-Morreale H.F et al. Non-classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency revisited: an update with a special focus on adolescent and adult women. Hum Reprod Update 2017; 23 (5): 580-99. DOI: 10.1093/humupd/dmx014][Amiri M, Ramezani Tehrani F, Nahidi F et al. Comparing the Effects of Combined Oral Contraceptives Containing Progestins With Low Androgenic and Antiandrogenic Activities on the Hypothalamic-Pituitary-Gonadal Axis in Patients With Polycystic Ovary Syndrome: Systematic Review and Meta-Analysis. JMIR Res Protoc 2018; 7 (4): 113. DOI: 10.2196/resprot.9024][Yonkers K.A, Cameron B, Gueorguieva R et al. The Influence of Cyclic Hormonal Contraception on Expression of Premenstrual Syndrome. J Womens Health (Larchmt) 2017; 26 (4): 321-8. DOI: 10.1089/jwh.2016.5941][Eisenlohr-Moul T.A, Girdler S.S, Johnson J.L et al. Treatment of premenstrual dysphoria with continuous versus intermittent dosing of oral contraceptives: Results of a three-arm randomized controlled trial. Depress Anxiety. 2017 Oct; 34 (10): 908-17. DOI: 10.1002/da.22673][Helvaci N, Yildiz B.O. Oral contraceptives in polycystic ovary syndrome. Minerva Endocrinol 2014; 39 (3): 175-87.][Bernstein L. The risk of breast, endometrial and ovarian cancer in users of hormonal preparations. Basic Clin Pharmacol Toxicol 2006; 98 (3): 288-96.][Gierisch J.M, Coeytaux R.R, Urrutia R.P et al. Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review. Cancer Epidemiol Biomarkers Prev 2013; 22 (11): 1931-43. DOI: 10.1158/1055-9965.EPI- 13-0298][Mihai Horga. Family planning training: challenges and opportunities in countries of Eastern Europe and Central Asia (EECA) region. Source: UN Population Division. World Contraceptive Patterns 2013.][Инструкция по препарату Линдинет 20. Справочник лекарств РЛС. 2018. [Instruktsiia po preparatu Lindinet 20. Spravochnik lekarstv RLS. 2018 .]]